A leading expert in nanotechnology and chemoprevention, Dr. Shin is a highly cited physician-scientist in the field of translational head and neck cancer research.
Titles and Roles
- Professor, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Adjunct Professor of Biomedical Engineering
- The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University
- Research Program
- Discovery and Developmental Therapeutics
Dong Moon Shin, MD, FACP, is the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research, Professor of Hematology/Medical Oncology, Professor of Otolaryngology, Professor of Biomedical Engineering, Director of the Head and Neck Cancer SPORE Program and Georgia Cancer Coalition Distinguished Scholar at the Winship Cancer Institute at Emory University. Dr. Shin has a highly successful scholar and research track record as a head and neck cancer investigator. He is a well established international and national recognized investigator in head and neck cancer research related to biology, biomarkers, chemoprevention, biochemoprevention, nanotherapeutics and molecularly-based innovative new therapy.
Dr. Shin graduated from Medical School in Yonsei University College of Medicine in Seoul, Korea in 1975. He completed Internships at Yonsei University Hospital in 1979 and at Cook County Hospital in Chicago in 1983. He also completed his Residency at Cook County Hospital in 1985 and his Fellowship at University of Texas, M.D. Anderson Cancer Center in Houston in 1988.
Dr. Shin’s research focus is in head, neck and lung cancers. During the past 30 years his research has been in the following areas: establishing carcinogenesis models in preclinical and clinical settings for head, neck and lung cancer; developing biomarkers in animal and human carcinogenesis for head, neck and lung cancer; developing molecular targeted prevention and therapies using epidermal growth factor receptor (EGFR) signaling pathways (i.e., EGFR monoclonal antibodies, EGFR tyrosine kinase inhibitors cyclooxygenase-2 (COX-2) inhibitors, other molecular targeted molecules and several natural compounds; and developing novel therapeutics (clinical or translational protocols) for head and neck cancer, lung cancer, thymoma and mesothelioma. He is also currently focused on new drug delivery to cancer patients using nanotechnology.
Below is a listing of current federal grants for the above principal investigator.
Dr. Shin has published over 240 peer reviewed scientific articles in journals such as The New England Journal of Medicine, The Journal of the National Cancer Institute, Cancer Research, and The Journal of Clinical Oncology. Dr. Shin’s research is widely cited in thousands of studies and peer reviewed papers.
Publications Publication Date
Dr. Shin is a recipient of the following awards:
- Clinical Oncology Career Development Award from American Cancer Society, 1994
- Faculty Scholar Award at the University of Texas M. D. Anderson Cancer Center, 2000
- Best Doctors in America, 2003-2014
- "Top Doctors" in Atlanta Magazine, 2005-2016
- America's Top Doctors in Cancer by Castle Connolly Medical Ltd. 2005-2014
- Georgia Cancer Coalition (GCC) Distinguished Scholar Award, 2005
- America's Top Oncologist in Cancer by Consumer's Research Council of America, 2007
- Cambridge Who's Who Life Time Member, 2007
- Francis Kelly Blomeyer Distinguished Chair in Cancer Research, 2008
- "MilliPub Club" Award from Emory University School of Medicine, 2011, 2015 and 2016
- Top Doctors featured in U.S. News & World Report, 2012/2013
- Korean Broadcasting System (KBS) Overseas Compatriots Award, 2015